Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02173782 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

892

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Berodual® Respimat ® high dose
DRUG: Berodual® Respimat ® low dose
DRUG: Berodual® MDI
DRUG: Placebo

Sponsor

Boehringer Ingelheim